



CANCER PREVENTION & RESEARCH INSTITUTE OF TEXAS

Award ID:
DP150039

Project Title:
Armada Pharmaceuticals Inc. New Company Formation for Development
of Anti-Cancer Antibody-Drug Conjugate Therapeutics

Award Mechanism:
New Company Product Development Award

Principal Investigator:
Tikhomirov, Iliia

Entity:
Formation Biologics Corporation

Lay Summary:

Armada Pharmaceuticals Inc is developing an innovative pipeline of targeted anti-cancer therapeutics called antibody-drug conjugates (ADCs). These next-generation treatments can have superior safety and efficacy. Armada's high-potential pipeline was developed using a cutting-edge platform integrating genomics, proteomics and bioinformatics technologies. Armada's lead product, AVID100, has been extensively studied in disease models, and demonstrated excellent safety and efficacy against many deadly cancers displaying the EGFR marker, including breast, ovarian, head and neck, glioma, pancreatic, gastric, and lung cancers. Compared to the FDA-approved anti-EGFR antibody Erbitux® (sales of ~\$2 billion/year), AVID100 demonstrated significantly superior activity against more types of cancers including those resistant to Erbitux®. This superior efficacy could help address significant unmet medical needs.

Armada is seeking to establish itself in Texas to advance clinical development of AVID100 and other candidates. Texas is home to outstanding scientific experts, and the clinical development infrastructure needed to swiftly advance its ADC candidates to FDA approval. M.D. Anderson Cancer Center is world-renowned for work on immunotherapy and ADCs. Locating Armada in Texas will expand local economy and oncology research capabilities, enable the training of experts in ADC production, and benefit Texas patients through enrolment in Armada's clinical trials, as early as 2015.